Cognition Therapeutics Narrows Focus to DLB Psychosis, Burns Cash
Event summary
- Cognition Therapeutics reported $37.0 million in cash and $35.7 million in remaining grant funds as of December 31, 2025, projecting sufficient runway through Q2 2027.
- The company is prioritizing zervimesine (CT1812) for the treatment of dementia with Lewy bodies (DLB) psychosis, following feedback from regulators.
- Enrollment is complete for the Phase 2 ‘START’ trial in early Alzheimer’s disease, with topline results expected in 2027.
- R&D expenses decreased to $37.2 million in 2025 from $41.7 million in 2024, driven by completed clinical trials.
The big picture
Cognition's strategic pivot towards DLB psychosis reflects the limited treatment options and unmet need in this patient population, but also concentrates risk on a single indication. The company's reliance on grant funding and its relatively short cash runway highlight the financial pressures inherent in early-stage drug development, particularly in neurodegenerative diseases where clinical trials are lengthy and expensive. The decision to deprioritize Alzheimer's, a much larger market, suggests a calculated gamble based on regulatory feedback and the potential for faster approval pathways for DLB psychosis.
What we're watching
- Regulatory Risk
- The upcoming FDA meeting regarding the DLB psychosis program will be critical; a negative outcome could significantly impact the company's valuation and development timeline.
- Clinical Execution
- The delayed topline results from the START trial in Alzheimer’s disease will dictate the future direction of zervimesine development, potentially leading to a shift in focus or abandonment of the program.
- Financial Sustainability
- The company's cash runway, while currently projected to extend through Q2 2027, will be heavily influenced by clinical trial costs and the success of securing additional grant funding.
Related topics